Facial Nerve Sacrifice During Parotidectomy for Metastatic Cutaneous Squamous Cell Carcinoma.
cutaneous squamous cell carcinoma
facial nerve
metastasis
parotidectomy
Journal
OTO open
ISSN: 2473-974X
Titre abrégé: OTO Open
Pays: United States
ID NLM: 101717942
Informations de publication
Date de publication:
Historique:
received:
17
09
2020
accepted:
08
12
2020
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
We analyzed the incidence of facial nerve sacrifice during parotidectomy for metastatic cutaneous squamous cell carcinoma (CSCC). We retrospectively reviewed the charts of patients with cutaneous squamous cell carcinoma. We used our CSCC institutional database, which includes patients treated at the University of California-Davis from 2001 to 2018. We evaluated patients who presented with biopsy-proven head and neck CSCC who underwent parotidectomy as a part of surgical treatment. We assessed the frequency of facial nerve sacrifice required in patients with normal preoperative facial nerve function with metastatic disease to the parotid. We evaluated the association between sacrifice and high-risk tumor variables using multivariate analysis. We identified 53 patients with parotid metastasis and normal preoperative facial nerve function. Thirteen percent of patients required sacrifice of the main trunk of the facial nerve and 27% required sacrifice of a branch of the facial nerve. All patients who underwent facial nerve sacrifice had extracapsular spread (ECS). Perineural invasion (PNI) in the primary tumor (odds ratio [OR], 9.11; Patients with regionally metastatic CSCC to the parotid gland frequently require sacrifice of all or a component of the facial nerve despite normal preoperative function. The likelihood of nerve sacrifice is highest for tumors with PNI and metastatic disease within the body of the parotid.
Identifiants
pubmed: 33718752
doi: 10.1177/2473974X21996627
pii: 10.1177_2473974X21996627
pmc: PMC7917942
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2473974X21996627Informations de copyright
© The Authors 2021.
Références
Ann Surg Oncol. 2019 Dec;26(13):4481-4488
pubmed: 31583542
Head Neck. 2005 Oct;27(10):851-6
pubmed: 16114004
Laryngoscope. 2005 Sep;115(9):1561-7
pubmed: 16148695
JAMA Dermatol. 2017 Aug 1;153(8):781-788
pubmed: 28678985
Am J Surg. 1995 Nov;170(5):446-50
pubmed: 7485729
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Head Neck. 2009 Jan;31(1):21-7
pubmed: 18767180
J Am Acad Dermatol. 1992 Jun;26(6):976-90
pubmed: 1607418
Cancer. 2013 Sep 15;119(18):3302-8
pubmed: 23797868
Aust N Z J Surg. 1992 Sep;62(9):697-701
pubmed: 1520151
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
Laryngoscope. 2005 May;115(5):870-5
pubmed: 15867656
Otolaryngol Head Neck Surg. 2014 Apr;150(4):610-7
pubmed: 24474713
Jpn J Clin Oncol. 2017 Aug 1;47(8):699-704
pubmed: 28430988
Otolaryngol Head Neck Surg. 2017 May;156(5):863-869
pubmed: 28322123
Head Neck. 2002 May;24(5):417-22
pubmed: 12001070
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Arch Dermatol. 2010 Mar;146(3):283-7
pubmed: 20231499